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affeine Prevents Protection in
wo Human Models of Ischemic Preconditioning
iels P. Riksen, MD,*† Zhigang Zhou, MD,* Wim J. G. Oyen, MD, PHD,‡ Rogier Jaspers, MD,§
art P. Ramakers, MSC,* Rene M. H. J. Brouwer, MD, PHD,§ Otto C. Boerman, PHD,‡
eil Steinmetz, MD, PHD, Paul Smits, MD, PHD,*† Gerard A. Rongen, MD, PHD*†
ijmegen, the Netherlands; and Boston, Massachusetts
OBJECTIVES We studied whether caffeine impairs protection by ischemic preconditioning (IP) in humans.
BACKGROUND Ischemic preconditioning is critically dependent on adenosine receptor stimulation. We
hypothesize that the adenosine receptor antagonist caffeine blocks the protective effect of IP.
METHODS In vivo ischemia-reperfusion injury was assessed in the thenar muscle by 99mTc-annexin A5
scintigraphy. Forty-two healthy volunteers performed forearm ischemic exercise. In 24
subjects, this was preceded by a stimulus for IP. In a randomized double-blinded design, the
subjects received caffeine (4 mg/kg) or saline intravenously before the experiment. At
reperfusion, 99mTc-annexin A5 was administered intravenously. Targeting of annexin was
quantified by region-of-interest analysis, and expressed as percentage difference between
experimental and contralateral hand. In vitro, we assessed recovery of contractile function of
human atrial trabeculae, harvested during heart surgery, as functional end point of ischemia-
reperfusion injury. Field-stimulated contraction was quantified at baseline and after simulated
ischemia-reperfusion, in a paired approach with and without 5 min of IP, in the presence
(n  13) or absence (n  17) of caffeine (10 mg/l).
RESULTS Ischemic preconditioning reduced annexin targeting in the absence of caffeine (from 13 3%
to 7  1% at 1 h, and from 19  2% to 9  3% at 4 h after reperfusion, p  0.006), but not
after caffeine administration (targeting 11  2% and 16  3% at 1 and 4 h). In vitro, IP
improved post-ischemic functional recovery in the control group, but not in the caffeine group
(8  3% vs. 8  5%, p  0.003).
CONCLUSIONS Caffeine abolishes IP in 2 human models at a dose equivalent to the drinking of 2 to 4 cups
of coffee. (The Effect of Caffeine on Ischemic Preconditioning; http://clinicaltrials.gov/ct/
show/NCT00184912?order1; NCT00184912). (J Am Coll Cardiol 2006;48:700–7)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.083© 2006 by the American College of Cardiology Foundation
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erief intermittent periods of ischemia and reperfusion
ender the myocardium more resistant to a subsequent more
rolonged period of ischemia and reperfusion. This phe-
omenon, which is called ischemic preconditioning (IP), is
he most powerful infarct size-limiting mechanism, other
han early reperfusion (1,2). In every animal species studied,
P reduced infarct size by approximately 75% (2). Also in
umans, several experimental models of ischemia-
eperfusion injury demonstrated protection by IP (3). Re-
ease of the endogenous nucleoside adenosine and subse-
uent stimulation of membrane-bound adenosine A1 and
3 receptors has been identified as a pivotal mechanism in
P (4–6).
Caffeine is a non-selective competitive antagonist of
denosine receptors. The plasma caffeine concentration
From the Departments of *Pharmacology-Toxicology, †Internal Medicine, ‡Nu-
lear Medicine, and §Cardiothoracic Surgery, Radboud University Nijmegen Medical
enter, Nijmegen, the Netherlands; and North American Scientific, Theseus
maging Division, Boston, Massachusetts. Dr. Riksen is the recipient of a fellowship
f the Netherlands Organisation of Scientific Research (ZonMw). Dr. Rongen is the
ecipient of a fellowship of the Royal Netherlands Academy of Arts and Sciences
KNAW). Additional financial support was obtained from the European Union
project number: QLK1-CT-2000-00069). Dr. Steinmetz is former Vice President of
heseus Imaging Corporation, the company that developed technetium-labeled
nnexin A5 as a tool to visualize apoptosis in humans in vivo.a
Manuscript received February 15, 2006; revised manuscript received April 4, 2006,
ccepted April 10, 2006.eached after regular coffee consumption is well within the
oncentration range that is needed to antagonize adenosine
eceptors (7). Based on this knowledge, we hypothesized
hat caffeine attenuates the cardioprotective effects of IP at
oncentrations that occur in daily life. A proof of this
ypothesis may have important implications for patients
ho are at risk for cardiac ischemia.
To address this hypothesis, we used 2 complementary
xperimental models of ischemia-reperfusion injury in
umans. In vivo 99mTc-annexin A5 scintigraphy of thenar
keletal muscle was used to study structural injury. This
odel is based on the highly specific binding of annexin A5
o phosphatidylserine residues, which are exposed on the
utside of cellular membranes early after an ischemic insult
8). In vitro we assessed post-ischemic recovery of contrac-
ile function of human atrial trabeculae as a functional end
oint of ischemia-reperfusion injury (9).
ETHODS
ubjects. Forty-two healthy male volunteers participated
n 2 in vivo studies. They were asked to abstain from
affeine-containing beverages for at least 24 h before the
xperiment. Forty-four patients awaiting cardiac surgery
greed to participate in the in vitro study. Patients with
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August 15, 2006:700–7 Caffeine Prevents Ischemic Preconditioningtrial arrhythmias, right ventricular failure, or patients who
ere treated with theophylline, oral antiarrhythmics, or
ulphonylureas were excluded because these drugs may
nterfere with IP. Written informed consent was obtained
rom all participants. Both protocols were approved by the
nstitutional Review Board of the Radboud University
ijmegen Medical Center.
xperimental protocols. IN VIVO STUDIES. Two random-
zed double-blinded studies were performed (Fig. 1). In all
ubjects, after cannulation of medial antecubital veins of
oth forearms, maximal voluntary contraction was deter-
ined in the non-dominant arm with a handgrip dyna-
ometer (Baseline Hydrolic Hand Dynamometer, Fabrica-
ion Enterprise Inc., Irvington, New York). In order to
nduce ischemia-reperfusion injury in thenar skeletal mus-
le, an ischemic exercise (Isch Ex) protocol was applied as
reviously described (8). In short, the circulation to the
orearm was occluded for 10 min by inflation of an upper
rm cuff to 200 mm Hg, which was combined with
sometric contractions of the finger flexors at 50% of
aximum contraction, performed rhythmically: 5 s of con-
raction followed by 5 s of relaxation until exhaustion. The
otal duration of ischemia was 10 min (index ischemia; Isch
x). Immediately upon reperfusion, radiolabeled annexin
5 (0.1 mg protein, 500 MBq Tc-99m) was administered
Abbreviations and Acronyms
IP  ischemic preconditioning
Isch Ex  ischemic exercise
igure 1. Schematic representation of the experimental protocol of the 2
ndicates the 10-min period of ischemia (without concomitant exercise); “Isch Ex”
andgripping.ntravenously into the dominant arm. Both hands were
maged simultaneously at 1 and 4 h after injection using a
amma camera (Siemens Orbiter, Hoffman Estates, Illi-
ois, equipped with low-energy high resolution collimators)
onnected to a Hermes Gold image processing system
Nuclear Diagnostics, Stockholm, Sweden) as previously
escribed (8).
In the first study (n  24), the Isch Ex was preceded by
0 min of ischemia only and 10 min of reperfusion (IP).
ubjects were randomized in a double-blinded fashion to
eceive either caffeine (4 mg/kg body weight intravenously
ver 10 min) or saline 35 min before the preconditioning
timulus.
To differentiate between a specific effect of caffeine on IP
ersus an effect on ischemia-reperfusion injury itself, a
econd study was performed. The set up of this second study
n  18) was similar to the first study, but now without a
reconditioning stimulus. The subjects also received caffeine
r saline in a randomized and double-blind fashion.
In all subjects, blood was drawn before administration of
affeine/saline and just before the ischemic episode for the
etermination of plasma caffeine concentration. In the
econd study, we used a Fin-A-Pres tonometer (Biomedical
nstrumentation, Neuilly, France) to record blood pressure
nd heart rate before caffeine/saline infusion and afterwards
just before the Isch Ex episode).
N VITRO STUDY. The experimental set up as described by
peechly-Dick et al. (9) was used with small modifications
o allow simultaneous measurement of 2 trabeculae from 1
atient. The right atrial appendage was harvested during
omized double-blinded in vivo studies. “IP” (ischemic preconditioning)rand
(ischemic exercise) indicates the 10-min period of ischemia with isometric
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Caffeine Prevents Ischemic Preconditioning August 15, 2006:700–7ardiac surgery before the introduction of the extracorporal
irculation and immediately placed in cold (4°C) modified
yrode’s solution (NaCl 118.5 mmol/l, KCl 4.8 mmol/l,
aHCO3 13 mmol/l, KH2PO4 1.2 mmol/l, MgSO4 1.44
mol/l, CaCl2 1.8 mmol/l, glucose 10.0 mmol/l, and
yruvate 10.0 mmol/l), which was continuously gassed with
5% oxygen and 5% CO2. Two atrial trabeculae (diameter
1 mm; length 3 mm) were dissected, vertically sus-
ended in an organ bath, and linked to a force transducer.
ach trabecula was superfused with pre-oxygenated Ty-
ode’s buffer (pO2 500 to 600 mm Hg). Electrical field
timulation was performed in unstretched condition at 1 Hz
sing platinum ring electrodes placed on both sides of the
rabeculae (pulse duration 60 ms; pulse current 40 mA).
fter 30 min of stimulation at unstretched conditions to
llow recovery from transportation and preparation, trabec-
lae were gradually stretched over 15 min until maximal
ontractile force was achieved. After 35 min of equilibra-
ion, a baseline recording was performed during 10 min.
hose trabeculae that failed to produce at least 0.2 g of
eveloped force at the end of baseline or in which the
oefficient of variation of developed force exceeded 20%
ere excluded (n  14).
Immediately after baseline recordings, for each patient
n  30) the 2 trabeculae were randomly assigned to either
stimulus for IP or continued superfusion with Tyrode’s
olution, so that from each patient 1 trabecula was precon-
itioned and the other was not. Ischemic preconditioning
as induced by 5 min of simulated ischemia and 5 min of
imulated reperfusion. Simulated ischemia was accom-
lished by superfusing the trabeculae with substrate-free
odified Tyrode’s solution (7.0 mM choline chloride sub-
tituted for glucose and pyruvate) and rapid pacing at 3 Hz.
he superfusate was pumped into an artificial lung filled
ith 95% N2/5% CO2, which resulted in a low pO2 of 10 to
0 mm Hg.
Subsequently, both trabeculae were subjected to 90 min
f simulated ischemia and 120 min of simulated reperfusion.
his protocol was performed in all patients who were
ncluded (n 30). In the last 13 patients, caffeine was added
o the superfusate at the end of equilibration at a final
oncentration of 10 mg/l.
ata recording and statistical analysis. All data are pre-
ented as mean  SE.
In the in vivo protocol, all digital scintigraphic images
ere analyzed off-line by the same blinded investigator
W.J.G.O.), using Hermes Gold software (Nuclear Diag-
ostics). Region-of-interest analysis was performed for the
henar muscle region in the hand. Radioactivity was ex-
ressed as counts per pixel. To correct for background
ctivity, the final result was expressed as the percentage
ifference between the experimental and control hand
“targeting”).
Baseline characteristics of the 4 groups were analyzed by
-way analysis of variance (ANOVA) followed by Scheffé’s sest for post-hoc comparisons (SPSS for Windows, release
2.0.1, SPSS Inc., Chicago, Illinois).
In the 2 randomized studies, differences in annexin
argeting between the groups were analyzed with a repeated
easures analysis of covariance (ANCOVA), with time
t  1 and t  4 h after injection) as within-subject factor,
roup (with and without caffeine pre-treatment) as
etween-subject factor, and workload (defined as the prod-
ct of maximal voluntary force and duration of Isch Ex) as
ovariate (SPSS for Windows, release 12.0.1, SPSS Inc.).
For each contraction of the trabeculae, we calculated
eveloped force (difference between maximal tension during
ontraction and minimal tension during relaxation), maxi-
al speed of tension development during contraction (mea-
ure of systolic function), and maximal speed of tension
eduction during relaxation (measure of diastolic function).
hese parameters were averaged for baseline, each subse-
uent 60-s period, and the last 10 min of final reperfusion.
unctional recovery was expressed as a percentage of base-
ine. Subsequently, the effect of IP was calculated as the
ifference in averaged percentage recovery between the 2
rabeculae during the final 10 min of reperfusion. A paired
tudent t test was used to compare control and precondi-
ioned trabeculae, and an unpaired Student t test was used
o compare groups with and without caffeine (SPSS for
indows, release 12.0.1, SPSS Inc.).
reparation of 99mTc-HYNIC-Annexin A5. Radiolabeled
nnexin A5 was freshly prepared before each experiment by
dding 99mTc-Pertechnetate (1,500 MBq) in the presence
f stannous tricine to succinimidylhydrazinonicotinamide
HYNIC)-conjugated recombinant human Annexin A5
NAS 2020, 0.275 mg per vial; Theseus Imaging Corp.,
oston, Massachusetts). For the second study (without
reconditioning), recombinant human Annexin A5 (ob-
ained from Theseus Imaging Corp.) was conjugated with
YNIC in our own laboratory. The radiolabeling procedure
f this HYNIC-conjugated Annexin A5 was identical to
hat of NAS 2020.
ESULTS
aseline characteristics. In both in vivo studies, subjects
ere randomized to caffeine or saline administration. As
uch, the 2 in vivo studies comprise 4 different groups:
aline-IP-Isch Ex, caffeine-IP-Isch Ex, saline-Isch Ex, and
affeine-Isch Ex. Baseline characteristics of these 4 groups
re shown in Table 1. There were no significant differences
etween the groups, except for heart rate (Table 1). Atrial
issue was obtained in 44 patients. According to the pre-
efined criteria, 14 patients were excluded from analysis.
here were no significant differences in clinical charac-
eristics between the groups with and without caffeine
Table 2).
n vivo studies. Plasma caffeine concentration just before
schemia was 0.2  0.1 mg/l and 6.1  0.4 mg/l in the first
tudy and 0.1  0.1 mg/l and 6.0  0.5 mg/l in the second
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August 15, 2006:700–7 Caffeine Prevents Ischemic Preconditioningtudy after saline and caffeine infusion, respectively. In the
econd study, we observed an increase in systolic and
iastolic blood pressure after caffeine administration
Table 3).
99mTc-annexin A5 targeting in the thenar muscle 1 and
h after reperfusion is shown in Figure 2. When comparing
he saline groups of both studies, IP reduced annexin
argeting from 13  3% to 7  1% at 1 h, and from 19 
% to 9  3% at 4 h after reperfusion (p  0.006, repeated
easures ANCOVA). In the first randomized study, caf-
eine significantly reduced the effect of preconditioning:
nnexin targeting was 11  2% and 16  3% at 1 and 4 h
p  0.04 vs. saline-IP-Isch Ex). In Figure 3, representative
cintigraphic images of the caffeine-IP-Isch Ex and saline-
able 1. Baseline Characteristics of the Groups in the In Vivo St
Saline-IP-Isch Ex
umber 12
ge (yrs) 25  1
eight (kg) 76  3
eight (cm) 186  2
BP (mm Hg) 124  3
BP (mm Hg) 76  2
eart rate (beats/min) 67  3
andom glucose (mmol/l) 4.8  0.2
verage coffee intake (cups/week) 11  4
orkload (kg·s) 10,000  1,058
aseline plasma caffeine (mg/l) 0.3  0.1
p  0.05 versus Caffeine-Isch Ex; 1-way analysis of variance followed by Scheffé’s
DBP  diastolic blood pressure; IP  ischemic preconditioning; Isch Ex  isch
able 2. Patient Characteristics of the 2 Study Groups in the
n Vitro Study
Control
Group
Caffeine
Group
umber 17 13
ender (male/female) 14/3 12/1
ge (yrs) 66.1  2.3 61.5  2.4
isk factors for atherosclerosis, n (%)
Hypertension 9 (52.9%) 7 (53.8%)
Diabetes mellitus 3 (17.6%) 2 (15.4%)
Hyperlipidemia 8 (47.1) 9 (69.2%)
Nicotine abuse 5 (29.4%) 6 (46.2%)
ndication for surgery
CABG 12 (70.6%) 12 (92.3%)
Aortic valve replacement 5 (29.4%) 1 (7.7%)
edication, n (%)
Beta-blocker 12 (70.6%) 12 (92.3%)
ACE inhibitor 5 (29.4%) 6 (46.2%)
Angiotensin II receptor antagonist 2 (11.8%) 0 (0%)
Calcium-channel blocker 8 (47.1%) 3 (23.1%)
Nitrate 9 (52.9%) 8 (61.5%)
Aspirin 11 (64.7%) 12 (92.3%)
HMG CoA reductase inhibitor 12 (70.6%) 9 (69.2%)
Insulin 1 (5.9%) 2 (15.4%)
erioperative medication, n (%)*
Volatile anesthetics 3 (25%) 5 (46%)
Opioids 12 (100%) 11 (100%)
This information could not be obtained in 5 subjects from the control group and 2
ubjects from the caffeine group.h
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass
rafting; HMG CoA  3-hydroxy-3-methylglutaryl coenzyme A.P-Isch Ex group are shown. However, in the second
andomized study, caffeine did not affect annexin targeting
fter only the Isch Ex procedure (13  3% at 1 h and 19 
% at 4 h for saline-Isch Ex and 12  3% and 18  3% for
affeine-Isch Ex; p  0.8).
n vitro study. Baseline contractile force was similar for all
roups of trabeculae (Table 4) (p 0.7, one-way ANOVA).
fter 90 min of simulated ischemia and 120 min of
eperfusion, only a partial recovery of contractile force was
bserved (Fig. 4). Ischemic preconditioning improved re-
overy from 43  3% to 51  4% (p  0.008), from 45 
% to 56 7% (p 0.055), and from 46 4% to 56 5%
p  0.017) for developed force, systolic and diastolic
unctions, respectively.
In the presence of caffeine, IP changed recovery in
ontractile function from 51  5% to 43  3% (p  0.10),
rom 51  5% to 44  3% (p  0.20), and from 54  5%
o 48  3% (p  0.20) for developed force, systolic and
iastolic functions, respectively. Thus, in the presence of
affeine, IP did no longer improve recovery of function. If
nything, a tendency to the contrary was observed. The
ffect of IP on recovery of contractile force differed signif-
cantly between the control group and the caffeine group
p  0.003).
ISCUSSION
affeine is one of the most widely consumed pharmacolog-
cally active compounds worldwide, mainly derived from
ietary sources such as coffee and tea (7). Daily intake of
affeine in U.S. consumers is estimated at 4 mg/kg per day,
hich is even higher in some European countries (10). In
he present study, we demonstrated that administration of
affeine, in a dose comparable to this estimated daily dose,
bolishes protection from IP in 2 experimental models in
umans.
Traditionally, IP is defined as myocardial infarct size
eduction induced by a preceding brief period of ischemia
nd reperfusion (1). In humans, however, this histologic end
oint cannot be used experimentally to study IP. Therefore,
everal surrogate end points of ischemia-reperfusion injury
feine-IP-Isch Ex Saline-Isch Ex Caffeine-Isch Ex
12 9 9
24  1 21  1 23  2
76  3 74  3 74  3
182  2 184  3 183  2
129  3 126  3 130  3
76  3 75  2 71  3
71  2* 61  2 60  3
4.4  0.3
11  3 13  2 9  3
9,147  594 7,219  642 7,179  886
0.4  0.2 0.1  0.0 0.2  0.1
oc test.
xercise; SBP  systolic blood pressure.udies
Cafave been developed to study IP in humans in an experi-
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Caffeine Prevents Ischemic Preconditioning August 15, 2006:700–7ental setting. In the present study, we used 2 different,
omplementary, and previously validated experimental
odels to study the effect of caffeine on IP in humans.
The in vivo part of our study is based on the specific and
igh-affinity binding of annexin A5 to phosphatidylserine
esidues on cellular membranes. It is well documented that
oss of membrane asymmetry is an early general feature of
poptosis, resulting in externalization of phosphatidylserine
esidues in affected cells, thus providing binding sites for
nnexin A5 (11,12). By labeling recombinant annexin A5
ith 99mtechnetium, it is possible to detect these cellular
hanges in vivo with a gamma camera. Previously, this
ethod has been used to visualize apoptotic cells in murine
nd human hearts in vivo (13,14). Concomitant use of
onventional methods for detection of apoptosis revealed
hat, indeed, annexin A5 specifically binds to cells with
poptotic morphology and co-localizes with the presence of
ctivated caspase-3 (15). Also, annexin A5 targeting could
e diminished by pre-treatment with caspase inhibitors
13). Because IP reduces myocardial ischemic injury in part
y inhibition of apoptosis (16), we used 99mTc-annexin A5
cintigraphy as a model to study IP in humans. We
emonstrated previously that 10 min of ischemia of the
on-dominant forearm combined with isometric handgrip
xercise (Isch Ex) increases targeting of annexin A5 to the
henar muscle, expressed as difference in 99mTc activity
etween the experimental and control hand (8). This
ncreased targeting could be prevented by a preconditioning
igure 2. Annexin A5 targeting in the thenar muscle at 1 (open bars) and
(solid bars) h after reperfusion in the different groups (expressed as
ercent difference between experimental and control hand). The p values
ndicate differences between groups as assessed by repeated measures
nalysis of covariance with time (t  1 and t  4 h after reperfusion)
s within-subject factor, group (as indicated on the x-axis) as between-
able 3. Hemodynamic Values at Baseline (Before Caffeine/Salin
aline) in the Group Without Preconditioning (the Second In Vi
Groups DBP Before DBP After
affeine (n  9) 73  2 87  3*
aline (n  7) 80  4 85  4
p  0.005 for effect of caffeine administration; †p  0.05 for comparison between
HR  heart rate; other abbreviations as in Table 1.r
ubject factor, and workload as covariate. IP  ischemic preconditioning;
sch Ex  ischemic exercise.timulus of 10 min ischemia and reperfusion before Isch Ex.
imilarly, pre-treatment with adenosine (administered into
he brachial artery) (8) and the nucleoside uptake inhibitor
ipyridamole (orally, twice daily for 1 week) (17) reduced
nnexin targeting.
In the present in vivo studies, we confirmed that, indeed,
he preconditioning stimulus reduced annexin A5 targeting
nduced by Isch Ex. In the first randomized trial, pre-
reatment with caffeine significantly reduced the effect of IP
n annexin targeting. In fact, annexin targeting in precon-
itioned subjects pre-treated with caffeine was similar to the
argeting in control subjects who were not preconditioned,
ndicating that the beneficial effect of IP is completely
bolished. In the second randomized trial, administration of
affeine did not affect annexin targeting after Isch Ex
ithout preconditioning, indicating that caffeine selectively
nhibits the effect of preconditioning on annexin targeting.
To confirm that these effects of caffeine are also present in
yocardial tissue, we performed an additional in vitro study
n human atrial trabeculae, obtained during heart surgery,
sing recovery of contractile function as an end point of
schemia-reperfusion injury. This model has been used in
everal previous studies, which consistently demonstrated
hat preconditioning increases post-ischemic recovery of
ontractile function (6,9,18–20). Also, these studies showed
hat preconditioning in this model is dependent on stimu-
ation of opioid receptors and protein kinase C, and opening
f KATP channels (9,18), and can be mimicked by stimula-
ion of adenosine A1 and A3 receptors, comparable to
tudies using histologic infarct size as an end point of
schemia-reperfusion injury (4,5,21–23). It has to be real-
zed that recovery of mechanical function after ischemia is
nfluenced by both the number of surviving myocytes and
he effect of stunning of these myocytes. The effect of
reconditioning on stunning is much more controversial
han its effect on cellular death (2). However, because in the
resent model of 90 min of ischemia an effect of precondi-
ioning has consistently been demonstrated, cellular death
robably plays a major role in determining functional
utcome.
In our study, the effect of IP was less than in previous
eports from other groups (6,9). Interestingly, this is com-
letely caused by the lower functional recovery of control
rabeculae in these previous reports. Differences in experi-
ental set up, patient group, and perioperative management
ould possibly account for this difference. For example, all
atients included in the present study received opioid
d Just Before the Ischemic Exercise Period (After Caffeine/
tudy)
Before SBP After HR Before HR After
 3 122  5*† 73  4 69  3
 5 114  4 68  4 67  5
of caffeine and effect of saline.e) an
vo S
SBP
107
113eceptor agonists, and approximately one-third of patients
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August 15, 2006:700–7 Caffeine Prevents Ischemic Preconditioningeceived volatile anesthetics before resection of the atrial
issue. Because these drugs mimic IP (24), this may have
esulted in improved functional recovery in the control
rabeculae compared with that in previous studies, leaving
igure 3. Representative scintigraphic images of the experimental and con
ith caffeine (A) and saline (B). Annexin targeting was 2% and 3% after sal
nd 27% after caffeine administration (caffeine-ischemic preconditioning-i
able 4. Baseline Contractile Force of the Different Groups of
rabeculae (Mean  SE)
Groups Baseline Force (g)
ontrol, IP 0.50  0.05
ontrol, no IP 0.47  0.05
affeine, IP 0.57  0.06
affeine, no IP 0.52  0.05iP  ischemic preconditioning.ess space for additional protection by IP. Unfortunately, in
hese previous studies, perioperative medication use was not
entioned. In the present study, post-ischemic recovery of
ontractile function was significantly increased by precon-
itioning in the saline group. In contrast, in the caffeine
roup, IP did not potentiate recovery of contractile function.
f anything, a reduction of functional recovery was observed
n the preconditioned trabeculae in the presence of caffeine.
nterestingly, recovery of contractile force in the non-
reconditioned trabeculae was higher in the caffeine group,
lthough this was not significant (p  0.2). Probably, this
eflects a transient positive inotropic effect of caffeine, which
ands at 1 and 4 h after reperfusion in preconditioned subjects pre-treated
ministration (saline-ischemic preconditioning-ischemic exercise) and 19%
ic exercise) at 1 and 4 h, respectively.trol h
ine ads observed as long as caffeine is present. Indeed, in the
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teady increase in contractile force in the 20 min immedi-
tely after administration of caffeine as compared with that
n the control trabeculae (data not shown). This is in
oncordance with previous studies demonstrating positive
notropic effects of xanthine derivatives (25,26). This could
e caused by antagonism of the negative inotropic effect of
ndogenous adenosine, which is continuously produced by
ardiomyocytes, although it is suggested that alternative
echanisms might also be involved (27). However, inhibi-
ion of phosphodiesterase and mobilization of intracellular
alcium is induced only at higher caffeine concentrations
han the concentration achieved in our study (7). This
ositive inotropic effect of caffeine is also present in the
reconditioned trabeculae, so any beneficial effect of pre-
onditioning should have increased recovery of contractile
orce as compared with the recovery without precondi-
ioning.
The plasma caffeine concentration immediately before
he initiation of forearm ischemia averaged approximately 6
g/l in the in vivo studies and was slightly higher in the in
itro study. This concentration occurs in daily life after an
ntake of 2 to 4 cups of coffee (28,29). At this concentration,
he pharmacologic actions of caffeine are solely due to
inding to adenosine receptors and antagonism of the
igure 4. The course of contractile force (expressed as percentage of baselin
open circles) preconditioning and in caffeine pre-treated trabeculae (n 1
or the effect of preconditioning on post-ischemic recovery of contractile
on-preconditioned groups are slight shifted to the right. IP  ischemicctions of endogenous adenosine. Other mechanisms of iction of caffeine, such as inhibition of phosphodiesterase or
alcium release from intracellular stores, occur at higher
oncentrations (7).
Impairment of the powerful infarct size-limiting effect of
P by caffeine would theoretically cause an association
etween caffeine use (especially derived from coffee con-
umption) and clinical end points of ischemia-reperfusion
njury. However, the association between coffee intake and
ardiovascular disease remains controversial, although for
ubjects consuming more than 5 cups of coffee daily, there
eems to be an increased risk for cardiovascular disease
30,31). Interestingly, a recent study showed that among
atients with a CYP1A2 genotype predicting slow caffeine
etabolism, intake of coffee (even 2 to 3 cups daily) was
ssociated with an increased risk of non-fatal myocardial
nfarction, suggesting that caffeine does play a role in this
ssociation (32). When considering these epidemiologic
rials in the light of our present results, it has to be realized
hat inhibition of preconditioning will not increase the
ncidence of cardiovascular events per se, but rather would
e expected to adversely affect the outcome after myocardial
nfarction (i.e., the incidence of cardiac failure or death) in
he subset of patients experiencing pre-infarction ischemia.
his potential effect has generally not been evaluated in
tudies on the association of coffee consumption and the
e) in time in control trabeculae (n  17) with (open squares) and without
th (filled squares) and without (filled circles) preconditioning. *p 0.008
in the saline group. For the sake of clarity, the symbols representing the
nditioning.e forc
3) wincidence of cardiovascular disease. Also, our study refers to
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August 15, 2006:700–7 Caffeine Prevents Ischemic Preconditioninghe acute effects of a single dose of caffeine. This does not
ecessarily hold for chronic use, especially because tolerance
o the pharmacologic effects of caffeine has been described
33). However, several publications have shown that a
onsiderable fraction of the population does not develop
omplete tolerance to caffeine despite the daily use of
affeinated products (34,35).
In conclusion, the present study shows that caffeine, at a
oncentration reached in daily life after drinking 2 to 4 cups
f coffee, impairs the protection afforded by IP in 2
xperimental models in humans. This observation provides
n experimental basis to study the effects of caffeine con-
umption on cardiovascular morbidity and mortality in
atients who are at increased risk for ischemic events.
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